In October 2012, a dream was realized for two dynamic ovarian cancer survivors: Anne Tonachel and Robin Bray. Their dream was to provide a restorative retreat for other ovarian cancer survivors in the northeast. When the amazing Kennedy family of Camp Kieve and The Kennedy Learning Center provided the retreat space (in honor of a family member with ovarian cancer), this restorative retreat was born.
This article appeared in The New England Journal of Medicine this past month. I have copied the abstract only. In addition, the editorial is also worth reading and I'm including it at the end.
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Willemien J. van Driel, M.D., Ph.D.,
Simone N. Koole, M.D.,
Karolina Sikorska, Ph.D.,
Jules H. Schagen van Leeuwen, M.D., Ph.D.,
Henk W.R. Schreuder, M.D., Ph.D.,
Ralph H.M. Hermans, M.D., Ph.D.,
Ignace H.J.T. de Hingh, M.D., Ph.D.,
Jacobus van der Velden, M.D., Ph.D.,
Henriëtte J. Arts, M.D., Ph.D.,
Leon F.A.G. Massuger, M.D., Ph.D.,
Arend G.J. Aalbers, M.D.,
Victor J. Verwaal, M.D., Ph.D.,
Jacobien M. Kieffer, Ph.D.,
Koen K. Van de Vijver, M.D., Ph.D.,
Harm van Tinteren, Ph.D.,
Neil K. Aaronson, Ph.D.,
and Gabe S. Sonke, M.D., Ph.D.
Treatment of newly diagnosed advanced-stage ovarian cancer typically involves cytoreductive surgery and systemic chemotherapy. We conducted a trial to investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery would improve outcomes among patients who were receiving neoadjuvant chemotherapy for stage III epithelial ovarian cancer.
This article was sent to me by a friend. Essentially, the article states that the BRCA1 gene can be normal but its function of DNA repair can be blocked by methylation. Methylation is a crucial part of DNA replication but hypermethylation can silence BRCA1.